April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Sarah Sammons: DPYD testing is required before our pharmacy will dispense capecitabine
Mar 16, 2024, 15:39

Sarah Sammons: DPYD testing is required before our pharmacy will dispense capecitabine

Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post by Vivek Subbiah on X/Twitter:

DPYD testing is required before our pharmacy will dispense capecitabine. If it’s policy, it’s done. It does delay the starting of the drug a few days but usually, this delay is in line with prior authorization delays anyway.”

Quoting Vivek Subbiah’s post:

DPYD Testing: Time to Put Patient Safety First in the Journal of Clinical Oncology.

Source: Sarah Sammons/X and Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.